Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 565-567 , April 2010

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles

  • Kevin Doody

      Affiliations

    • Center for Assisted Reproduction, Bedford, Texas, USA
    • ,
  • Paul Devroey

      Affiliations

    • Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Belgium
    • ,
  • Keith Gordon

      Affiliations

    • Global Medical Affairs, Schering-Plough Kenilworth, NJ, USA
    • ,
  • Han Witjes

      Affiliations

    • Schering-Plough Research Institute, Oss, The Netherlands
    • ,
  • Bernadette Mannaerts

      Affiliations

    • Schering-Plough Research Institute, Oss, The Netherlands
    • Corresponding Author InformationCorresponding author.

Received 2 July 2009 ,Revised 21 September 2009 ,Accepted 30 November 2009.

References 

  1. Bosch E, Escudero E, Crespo J, et al. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome. Fertil. Steril. 2005;84:1529–1532
  2. Bosch E, Vidal C, Labarta E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists – a randomized study. Hum. Reprod. 2008;23:2346–2351
  3. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. 2004;19:1979–1984
  4. Devroey P, Boostanfar R, Koper NP, et al. for the ENGAGE Investigators A double-blind, non-inferiority, RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum. Reprod. 2009;24:3063–3072
  5. Griesinger G, Schultze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum. Reprod. 2005;20:1200–1206
  6. Kolibianakis EM, Zikopoulos K, Schiettecatte J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum. Reprod. 2004;19:2490–2496
  7. Merviel P, Antoine JM, Mathieu E, et al. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil. Steril. 2004;82:119–125

 Kevin Doody, MD, received his medical degree and served a residency in Obstetrics and Gynecology at Baylor College of Medicine in Houston. After completing his residency, Dr Doody received subspecialty training at UT Southwestern Medical Center. He completed his fellowship in Reproductive Endocrinology/Infertility in 1989. He is board certified in Obstetrics and Gynecology and subspecialty board certified in Reproductive Endocrinology/Infertility. Dr Doody has been repeatedly honored as one of Fort Worth’s Top Docs, one of Texas’ Super Doctors and one of the Best Doctors in America. Dr Doody was also recognized as Microsoft Physician of the Year 2004.

PII: S1472-6483(09)00303-4

doi: 10.1016/j.rbmo.2009.12.019

Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 565-567 , April 2010

Article Tools

* Image Usage & Resolution